DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced that it has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous Glucose Monitoring (“CGM”) biosensor device in China and India. This Letter of Intent is related to the Company’s recently announced acquisition of the CGM assets of Waveform Technologies, Inc.  Trinity has entered into a Letter of Intent with Bayer’s subsidiary in China under which both parties confirmed their intent to further explore an exclusive joint partnership between the Company and Bayer for the launch of a CGM focused biosensor device into the Chinese market (the “China Joint Partnership”).

爱尔兰都柏林，2024年1月31日（环球通讯社）--Trinity Biotech plc（纳斯达克：TRIB）（“公司”）今天宣布，它已与拜耳签订了一份不具约束力的意向书，在中国和印度推出连续血糖监测（“CGM”）生物传感器设备。本意向书与公司最近宣布收购波形技术CGM资产有关，Trinity公司已与拜耳在中国的子公司签订了一份意向书，根据该意向书，双方确认有意进一步探索公司与拜耳之间的独家合资伙伴关系，以将以CGM为重点的生物传感器设备投放中国市场（“中国合资伙伴关系”）。

Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months. The China Joint Partnership intends to leverage Bayer's significant and well-established presence in the Chinese healthcare market, particularly in diabetes, and is intended to lead to the launch of a low cost of care, high quality, CGM device designed to increase affordability and accessibility of diabetes care.

双方打算在未来几个月内，在意向书设定的框架下谈判达成最终协议。中国联合伙伴关系旨在利用拜耳在中国医疗保健市场（尤其是糖尿病市场）的重要地位，并旨在推出一种低成本、高质量的CGM设备，旨在提高糖尿病护理的可负担性和可获得性。

Diabetes is a major health concern in China, with a significant and rapidly growing diabetes prevalence rate. Factors such as urbanisation, dietary changes and sedentary lifestyles have contributed to the escalation of Type 2 diabetes across China, creating a pressing need for innovative and low cost of care solutions to manage and combat this condition.

糖尿病是中国的主要健康问题，糖尿病患病率显着且迅速增长。城市化，饮食变化和久坐的生活方式等因素导致了中国2型糖尿病的升级，迫切需要创新和低成本的护理解决方案来管理和应对这种情况。

In addition to the proposal to enter the Chinese market, the Letter of Intent includes a framework for the intention to launch a CGM device in India. India faces a significant public health challenge with over 100 million people living with diabetes and a rise in both Type 1 an.

除了进入中国市场的提议外，意向书还包括在印度推出CGM设备的意向框架。印度面临着重大的公共卫生挑战，有1亿多人患有糖尿病，1型糖尿病和1型糖尿病的发病率都在上升。